In a remarkable display of resilience, shares of Cocrystal Pharma Inc. (COCP), a $31 million market cap company, soared to a 52-week high, reaching a price level of $3.1. According to InvestingPro data, the stock has demonstrated strong momentum with a 44% gain year-to-date. This peak comes as a significant milestone for the company, reflecting a period of robust performance and investor confidence. Over the past year, the stock has witnessed an impressive rally, with Biozone Pharm, its parent company, reporting a staggering 1-year change of 70.86%. With analyst price targets ranging from $7 to $10, and a “FAIR” financial health rating from InvestingPro, which notes the company holds more cash than debt, this surge underscores the positive sentiment surrounding the company’s prospects and the broader biopharmaceutical sector’s potential for innovation and growth.
In other recent news, Cocrystal Pharma has made significant adjustments to its executive compensation packages, which includes salary increases, bonuses, and restricted stock unit (RSU) grants. Co-Chief Executive Officers James Martin and Dr. Sam Lee have seen their base salaries rise to $416,000, and they have also received a bonus of $200,000 and a grant of 40,000 RSUs. The company’s non-employee directors have also been awarded cash stipends and RSU grants, with specific vesting conditions in place.
In further developments, Cocrystal Pharma has initiated the multiple-ascending dose phase of their Phase 1 clinical trial for CDI-988, a broad-spectrum oral pan-viral protease inhibitor. This follows a successful single-ascending dose phase completed in 2024. The company anticipates topline results from this phase of the CDI-988 study in late 2024 or early 2025.
In terms of capital structure, Cocrystal Pharma has reduced the number of authorized capital stock from 155 million to 101 million shares. Analysts from H.C. Wainwright have maintained a neutral rating on the company, adjusting their price target to $7.00. Meanwhile, Noble Capital has retained its Outperform rating, expressing optimism about the future outcomes of the CC-42344 Influenza Virus Program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
